论文部分内容阅读
目的探讨血清中血管内皮生长因子(VEGF)、CA15-3、CA125和癌胚抗原(CEA)检测在乳腺癌预后判断中的表达及其临床意义。方法用免疫组化(S-P)法动态监测93例乳腺癌患者的VEGF水平,用放射免疫法检测CA15-3、CA125和CEA的水平,并与25例健康体检者的各项指标进行比较,分析其与临床分期、治疗效果和复发转移的关系。结果乳腺癌组的VEGF阳性率显著高于正常对照组,且乳腺癌Ⅰ~Ⅳ期健康状况依次升高,有淋巴结转移者较无转移患者高,差异有统计学意义(P<0.01);乳腺癌患者中Ⅲ、Ⅳ期的CA15-3、CA125和CEA水平也明显高于正常对照组和Ⅰ、Ⅱ期患者,有淋巴结转移者显著高于无淋巴结转移患者,差异均有统计学意义(P<0.05);随访中发现复发者各项指标均比无复发者高;VEGF、CA15-3、CA125和CEA的表达与临床分期、腋窝淋巴结状况有关(P<0.01),但与患者年龄、肿瘤大小和肿瘤病理学类型无关(P>0.05)。结论VEGF、CA15-3、CA125和CEA的检测对于判断乳腺癌的分期、转移情况及治疗效果的评价有一定意义,可以指导临床对乳腺癌的诊疗工作。
Objective To investigate the expression and clinical significance of serum vascular endothelial growth factor (VEGF), CA15-3, CA125 and carcinoembryonic antigen (CEA) in the prognosis of breast cancer. Methods The VEGF level of 93 breast cancer patients was dynamically detected by immunohistochemistry (SP) method. The levels of CA15-3, CA125 and CEA were detected by radioimmunoassay and compared with those of 25 healthy subjects Its relationship with clinical stage, therapeutic effect and recurrence and metastasis. Results The positive rate of VEGF in breast cancer group was significantly higher than that in normal control group, and the health status of patients with stage Ⅰ ~ Ⅳ breast cancer were successively higher than those without lymph node metastasis, the difference was statistically significant (P <0.01) The levels of CA15-3, CA125 and CEA in stage Ⅲ and Ⅳ of cancer patients were also significantly higher than those in normal control group and stage Ⅰ and Ⅱ patients, and those with lymph node metastasis were significantly higher than those without lymph node metastasis (P <0.05). The recurrences were found to be higher in recurrence than those without recurrence. The expression of VEGF, CA15-3, CA125 and CEA were correlated with clinical stage and axillary lymph node status (P <0.01), but not with age, The size was not related to tumor pathology (P> 0.05). Conclusion The detection of VEGF, CA15-3, CA125 and CEA has some significance for the evaluation of staging, metastasis and therapeutic effect of breast cancer, and can guide clinical diagnosis and treatment of breast cancer.